Biogen has reached a final agreement to pay $900 million to resolve previously disclosed qui tam litigation relating to speaker and consultant programs conducted by the Company prior to 2015. Biogen believes its intent and conduct was at all times lawful and appropriate and Biogen denies all allegations raised in this case. The U.S. and the states did not intervene in the case and the settlement does not include any admission of liability by Biogen.
Biogen determined that now was the right time to resolve the litigation and allow the Company to remain focused on our patients and strategic priorities. Biogen continues to believe that it is important to equip physicians and patients with the information needed to make the best decisions for their care.*
*The above includes forward-looking statements, which speak only as of the date they were made. Please consult the risk factors section of our SEC filings.